L'intérêt à découvert pour enVVeno Medical donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de enVVeno Medical. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

enVVeno Medical (NASDAQ:NVNO) Stock, Rapport sur les intérêts à découvert

enVVeno Medical

enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

enVVeno Medical Corporation - Common Stock

enVVeno Medical Corp

Wells Fargo analyst George Kelly maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $800 to $850.

News

Price Target

Analyst Ratings

COST

Wells Fargo Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $850

Struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)&nbsp;continues to receive <a target="_blank" href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo" rel="noreferrer noopener">takeover proposals from</a> chip companies, the latest being Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) following Qualcomm Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) proposal earlier.
Arm Holdings recently proposed to acquire Intel&#8217;s product unit. However, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-27/arm-rejected-by-intel-after-approaching-it-about-buying-product-unit?sref=TBDibEcD" rel="noreferrer noopener">reports</a> that Intel is not looking to sell the business division.
Intel stock plunged 31% as it failed to capitalize on the artificial intelligence shift, which is something that contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) excelled at.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/41012678/super-micro-unveils-next-gen-servers-powered-by-intels-latest-xeon-chips" rel="noreferrer noopener">Super Micro Unveils Next-Gen Servers Powered by Intel&#8217;s Latest Xeon Chips</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png" alt="" class="wp-image-569782" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Meanwhile, some reports indicated Intel&#8217;s plans to convert its <a target="_blank" href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" rel="noreferrer noopener">foundry business into</a> an independent unit, including exploring a spinoff into a publicly traded company. The chipmaker also explored divesting stake in the programmable chip unit&nbsp;Altera.
However, Intel&#8217;s recent big wins included a&nbsp;U.S. chipmaking deal from&nbsp;Amazon.Com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web services and the U.S. Chip grant.
The chipmaker also clarified that it would not divest a majority stake in the struggling <a target="_blank" href="https://www.benzinga.com/news/24/09/40941075/whats-going-on-with-autonomous-driving-stock-mobileye-thursday" rel="noreferrer noopener">Israeli autonomous driving company</a> Mobileye Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), whose stock is down 66% in the last 12 months.
Intel&#8217;s exploration of stake sales to companies like Qualcomm and Arm could hinder its U.S. subsidy over antitrust grounds, the Financial Times <a target="_blank" href="https://www.ft.com/content/ff0ca77d-ad35-45ba-a493-201a26932efb" rel="noreferrer noopener">reports</a>.
Multiple deals including Nvidia&#8217;s proposal to snap Arm Holdings from&nbsp;Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and Intel&#8217;s&nbsp;Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) deal have succumbed to global regulatory opposition.
The semiconductor sector had a good week, buoyed by the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41046485/whats-going-on-with-nvidia-braodcom-intel-and-other-chip-stocks-on-thursday" rel="noreferrer noopener">key rate cuts</a> in the U.S. and China, an upbeat quarterly print from Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and continued AI investments from Big Tech companies.
Semiconductor ETFs, Invesco Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSI#NYSE">PSI</a>) and SPDR S&amp;P Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XSD#NYSE">XSD</a>), gained 5%- 7% in the last five days.
Price Action: INTC stock is down 0.04% at $23.91 at the last check on Friday.
Photo via Shutterstock

Tech

Media

AAPL

AMZN

INTC

MBLY

NVDA

PowerShares Exchange-Traded Fund Trust Dynamic Semiconductor Portfolio

QCOM

SFTBF

SFTBY

TSEM

What's Going On With Intel Stock On Friday?

Politics

General

Multiple Blasts Heard In Beirut, According To Reuters Witness, 'Massive Thick Clouds Of Smoke' Rising From City

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $10 price target.

Reiteration

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

On CNBC: Tanger Outlet CEO Discusses Shopping Trends, Consumer Demand

WIIM

GDRX

PETS

Shares of pharmacy stocks are trading higher. Costco on its earnings call said pharmacy had the strongest sales percentage increase within ancillary businesses, with a double-digit script count growth, which could possibly be lifting the sector.

High-rolling investors have positioned themselves bullish on McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MCD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for McDonald's. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 12% bearish. Among all the options we identified, there was one put, amounting to $107,640, and 7 calls, totaling $441,864.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $145.0 and $440.0 for McDonald's, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in McDonald's's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to McDonald's's substantial trades, within a strike price spectrum from $145.0 to $440.0 over the preceding 30 days.
<h3>McDonald's Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450251_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$163.9</td>
<td>$161.1</td>
<td>$162.7</td>
<td>$145.00</td>
<td>$113.8K</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$136.9</td>
<td>$132.5</td>
<td>$134.55</td>
<td>$440.00</td>
<td>$107.6K</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$2.9</td>
<td>$2.72</td>
<td>$2.9</td>
<td>$305.00</td>
<td>$66.7K</td>
<td>2.4K</td>
<td>355</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/04/24</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.53</td>
<td>$305.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$3.1</td>
<td>$2.96</td>
<td>$3.1</td>
<td>$305.00</td>
<td>$62.0K</td>
<td>2.4K</td>
<td>642</td>
</tr>
</tbody>
</table>

<h3>About McDonald's</h3>
McDonald's is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
Following our analysis of the options activities associated with McDonald's, we pivot to a closer look at the company's own performance.
<h3>Current Position of McDonald's</h3>
<ul>
<li>With a volume of 533,349, the price of MCD is up 0.94% at $306.51. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 31 days.</li>
</ul>
<h3>What Analysts Are Saying About McDonald's</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $303.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on McDonald's, maintaining a target price of $325. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Hold, adjusting the price target to $280. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on McDonald's, maintaining a target price of $301. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for McDonald's, targeting a price of $320. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on McDonald's, which currently sits at a price target of $290. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McDonald's, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On McDonald's

Whales with a lot of money to spend have taken a noticeably bullish stance on Bitdeer Technologies.
Looking at options history for Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $112,000 and 6, calls, for a total amount of $567,404.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $10.0 for Bitdeer Technologies, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Bitdeer Technologies options trades today is 6177.5 with a total volume of 10,120.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Bitdeer Technologies's big money trades within a strike price range of $5.0 to $10.0 over the last 30 days.
<h3>Bitdeer Technologies Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450246_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$285.9K</td>
<td>4.5K</td>
<td>819</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.45</td>
<td>$2.25</td>
<td>$2.27</td>
<td>$7.50</td>
<td>$107.1K</td>
<td>9.5K</td>
<td>740</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.4</td>
<td>$0.35</td>
<td>$0.35</td>
<td>$7.50</td>
<td>$81.8K</td>
<td>3.4K</td>
<td>2.3K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.0</td>
<td>$2.3</td>
<td>$2.35</td>
<td>$10.00</td>
<td>$54.6K</td>
<td>7.2K</td>
<td>839</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.05</td>
<td>$2.27</td>
<td>$7.50</td>
<td>$45.4K</td>
<td>9.5K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Bitdeer Technologies</h3>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
Following our analysis of the options activities associated with Bitdeer Technologies, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Bitdeer Technologies</h3>
<ul>
<li>Currently trading with a volume of 830,932, the BTDR's price is up by 4.06%, now at $8.32. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 45 days.</li>
</ul>
<h3>What The Experts Say On Bitdeer Technologies</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $13.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $13. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $14. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Bitdeer Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

BTDR

Bitdeer Technologies's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SAVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Cassava Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 46%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $1,182,634, and 4 are calls, for a total amount of $186,612.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $60.0 for Cassava Sciences during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cassava Sciences stands at 624.67, with a total volume reaching 6,170.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cassava Sciences, situated within the strike price corridor from $10.0 to $60.0, throughout the last 30 days.
<h3>Cassava Sciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450241_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.1</td>
<td>$5.05</td>
<td>$5.05</td>
<td>$25.00</td>
<td>$452.0K</td>
<td>153</td>
<td>5</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.4</td>
<td>$7.35</td>
<td>$7.35</td>
<td>$30.00</td>
<td>$166.8K</td>
<td>105</td>
<td>234</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.15</td>
<td>$2.8</td>
<td>$3.15</td>
<td>$20.00</td>
<td>$164.7K</td>
<td>902</td>
<td>273</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.2</td>
<td>$5.15</td>
<td>$5.15</td>
<td>$25.00</td>
<td>$110.7K</td>
<td>153</td>
<td>1.1K</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.55</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$60.00</td>
<td>$85.5K</td>
<td>1.4K</td>
<td>115</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Having examined the options trading patterns of Cassava Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Cassava Sciences</h3>
<ul>
<li>Trading volume stands at 3,473,313, with SAVA's price down by -13.12%, positioned at $27.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cassava Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SAVA

Cassava Sciences Unusual Options Activity

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41067118/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-with-copd" rel="noreferrer noopener">eosinophilic phenotype</a>, generally known as &#8220;smoker&#8217;s lung.&#8221;
Dupixent is the first biologic medicine approved in the U.S. to treat these patients.&nbsp;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease</a>.
The FDA approval is based on data from two Phase 3 trials (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=7kKUkEN_j7dfFFaJgSlNFzKZoO4mFwp3ozmSi0rwdtS0dUmDMMLRg3ML03GEfgLzJP_Yg33hoRBP-3IabEFUjTEGB_rbTRFqm_JL_llzjsfHVLX2ednnpkFojo7lpUCTxdCo_2YiyMr0ctlswWAwXOheTav4f6f3NjyHRNKi9AkNKqyHtmSD_t9WycxSdyDJF-7MluPxoOJfAy9kkVjGMA==" rel="noreferrer noopener">BOREAS</a> and&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=6PGgHroz2kXLk3EuPbMe_MIJ-5vFWDjqk9axy8qZd2P7xQ3L3g2ASjHZ8xt1uzCTdZuMSDrpF3jIDhOGYYWxNY22Nyhv04bkd8VwfNHxSVov8kQjYXAerk1eaKGoDXJDxNmLd9JxB76ojM5ft65Yy_p10fVEAMfMBBDCl7C-sv2-eIX7C8dxYBsnfHK7AYcbsomWIUjlfALjFhRk2bqT3w==" rel="noreferrer noopener">NOTUS</a>) that evaluated the efficacy and safety of Dupixent compared to placebo in adults currently on maximal standard-of-care inhaled therapy (nearly all on triple therapy).
<ul>
<li>Patients who received Dupixent in BOREAS (n=468) and NOTUS (n=470) experienced the following outcomes, respectively, compared to placebo (BOREAS n=471; NOTUS n=465):</li>
<li>The primary endpoint is a 30% and 34% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks.</li>
<li>74mL and 68mL numerically greater improvements in post-bronchodilator FEV1 from baseline at week 12 compared to placebo, sustained at 52 weeks. Statistically significant improvements of similar magnitude were observed in pre-bronchodilator FEV1 from baseline at 12 and 52 weeks, a key secondary endpoint.</li>
<li>51% response in a health-related quality of life measure in both trials compared to 43% and 47% with placebo at 52 weeks.</li>
</ul>
About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy.
In the U.S., approximately 300,000 people live with inadequately controlled COPD and an eosinophilic phenotype.
Patients with an eosinophilic phenotype contribute to a ~30% increase in exacerbations and an increased risk of COPD-related re-hospitalizations within a year.
Today, China&#8217;s National Medical Products Administration also approved Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41063987/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic" rel="noreferrer noopener">raised blood eosinophils</a>.
The approval is based on BOREAS and NOTUS Phase 3 trial results.
Price Action:&nbsp;At last check Friday, REGN stock was up 2.86% at $1,069.75, and SNY stock was up 1.49% at $57.85.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41067826/federal-investigations-continue-for-psychiatric-hospital-chain-operator-acadia-healthcare-even-aft" target="_blank" rel="noreferrer noopener">Federal Investigations Continue For Psychiatric Hospital Chain Operator Acadia Healthcare Even After $20M Settlement Over False Claims Allegations</a>.</li>
</ul>

Biotech

Large Cap

Health Care

Movers

Trading Ideas

REGN

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

AGIO

Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.

Senator Ron Wyden (D-OR) introduced the Cannabinoid Safety and Regulation Act (CSRA) on Wednesday, aiming to establish a federal framework for regulating hemp-derived cannabinoids like <a href="http://benzinga.com/topic/CBD">CBD</a> and <a href="https://www.benzinga.com/markets/cannabis/24/01/36584043/real-weed-or-a-lab-high-delta-8-and-delta-9-thc-explained">Delta-8 THC</a>. The legislation seeks to protect public health by setting national standards on age restrictions, safety testing and labeling for <a href="http://benzinga.com/topic/hemp">hemp</a> products.
<h3 class="wp-block-heading">FDA To Oversee Hemp Product Safety And Access</h3>
Wyden&#8217;s CSRA proposes a national age limit of 21 for purchasing <a href="https://www.benzinga.com/markets/cannabis/24/07/39975361/hemp-derived-cannabinoids-vs-legal-cannabis-what-industry-members-are-saying-about-this-not-so-s">hemp-derived cannabinoid</a> products and mandates that all such products undergo safety and manufacturing testing to ensure clean processes. The bill empowers the Food and Drug Administration (FDA) to recall or ban cannabis products <a href="https://www.benzinga.com/markets/cannabis/24/07/39915334/a-nasty-high-experts-sound-alarm-over-soup-of-unknown-compounds-in-hemp-derived-thc-products">containing dangerous chemicals or additives</a>, ensuring truth in labeling.
&#8220;Just like the tobacco industry marketing cigarettes to young people, nobody should be slapping fun cartoons and glitzy candy wrapper packaging on cannabis products meant for adults,&#8221; Wyden <a href="https://www.wyden.senate.gov/news/press-releases/wyden-introduces-legislation-to-clean-up-hemp-market-keep-products-out-of-kids-hands">stated</a> in a press release. &#8220;A federal floor for regulation of hemp products is non-negotiable to ensure that consumers aren't put at risk by untested products of unknown origin. My legislation will ensure that adult consumers know what they're getting, and that hemp products are never sold or marketed to children.&#8221;
<h3 class="wp-block-heading">Synthetic Cannabinoids Would Face Federal Ban</h3>
The <a href="https://www.wyden.senate.gov/download/csra">legislation</a> allows states to impose their own regulations on hemp-derived products beyond the bill&#8217;s provisions. It also bans &#8220;artificially or synthetically derived cannabinoids and semi-synthetic cannabinoids,&#8221; <a href="https://www.wyden.senate.gov/imo/media/doc/cannabinoid_safety_and_regulation_act_section-by-sectionpdf.pdf">defined</a> as those produced through chemical synthesis, modification or conversion. The bill would prohibit adding cannabinoids to products containing alcohol, tobacco, nicotine or other substances that could interact with or enhance cannabinoid effects.
Synthetically derived cannabinoids like Delta-8 THC would also be federally banned. This means products containing Delta-8 THC synthesized from legal CBD would become illegal, significantly impacting their availability in state markets where they&#8217;re now being sold.
Further, the bill would establish a new FDA department, the Center for Cannabinoid Products, which would enforce bans on synthetically derived cannabinoids and regulate dosages in hemp products.
<h3 class="wp-block-heading">Industry Groups Back Wyden&#8217;s Hemp Bill</h3>
Co-sponsored by Senator Jeff Merkley (D-OR), the CSRA has garnered support from key industry groups, including the U.S. Hemp Roundtable and the National Cannabis Industry Association. 
&#8220;The hemp industry is united behind a simple, common-sense proposition: Hemp products should be robustly regulated, not the subject of a misguided prohibition,&#8221; said Jonathan Miller, general counsel at the U.S. Hemp Roundtable.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">Expert Calls For A United Hemp And Cannabis Front, &#8216;Industries Should Collaborate&#8217; And Push For Federal Rules</a>
Clifford Starke, chairman and CEO of Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>), <a href="https://www.newsfilecorp.com/release/224598/Flora-Growth-Corp.-Applauds-Senator-Wyden-for-Introducing-the-Cannabinoid-Safety-and-Regulations-Act?k=cannabis">expressed</a> his support for the bill. &#8220;The introduction of the Cannabinoid Safety and Regulation Act represents a pivotal step forward for the cannabis and hemp industries. By establishing clear regulatory standards, this bill will not only protect public health and safety but also create a robust legal pathway for companies like Flora to deliver safe, high-quality cannabinoid products to adults. Importantly, it ensures that these products are rigorously tested, properly labeled, and age-restricted,&#8221; Starke <a href="https://www.newsfilecorp.com/release/224598/Flora-Growth-Corp.-Applauds-Senator-Wyden-for-Introducing-the-Cannabinoid-Safety-and-Regulations-Act?k=cannabis">stated</a> in a press release.
Wyden&#8217;s proposal emerges amid <a href="https://www.benzinga.com/markets/cannabis/24/07/39610764/intoxicating-hemp-products-face-regulatory-crackdown-across-multiple-states">growing state-level actions</a> to regulate or <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">ban synthetic hemp products</a>. The bill aims to address regulatory gaps that have <a href="https://www.benzinga.com/markets/cannabis/24/07/39783607/how-hemp-became-americas-loophole-for-legal-highs">existed since the 2018 Farm Bill</a>, which legalized hemp production but inadvertently opened the market to unregulated, psychoactive hemp-derived products like delta-9 THC <a href="https://www.benzinga.com/markets/cannabis/23/10/35305062/hemp-derived-thc-edibles-in-nostalgic-flavors-like-saltwater-taffy-freeze-pops-now-available-nat">edibles</a> and <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">beverages</a>.
<h3 class="wp-block-heading">Congressional Delays, Potential Backlash</h3>
While the CSRA seeks to balance consumer safety with industry growth, its passage remains uncertain due to legislative gridlock in Congress, <a href="https://mjbizdaily.com/hemp-bill-introduced-in-us-senate-would-ban-synthetic-thc/">notes</a> MJBizDaily. With challenges in advancing basic funding bills, more complex legislation like the CSRA may face delays.
Furthermore, the bill could spark controversy akin to recent events in Missouri and California, where regulatory actions on hemp-derived products <a href="https://www.benzinga.com/markets/cannabis/24/09/40945349/cannabis-companies-have-missouris-governor-beat-hemp-thc-products-sales-resume-as-stricter-contr">faced legal challenges and industry backlash</a>. Critics argue that such measures might inadvertently <a href="https://www.benzinga.com/markets/cannabis/24/09/40906131/this-is-life-or-death-families-of-disabled-children-panic-over-gov-newsoms-hemp-cbd-ban-and-eval">harm patients dependent on hemp-derived CBD treatments</a> and negatively impact the hemp industry, suggesting Wyden&#8217;s proposal may encounter similar opposition.
<h3 class="wp-block-heading">Impact On Hemp Investments</h3>
For investors, the introduction of the CSRA signals potential market shifts in the hemp and <a href="http://benzinga.com/cannabis">cannabis</a> industries. Increased regulation could impact companies <a href="https://www.benzinga.com/markets/cannabis/24/08/40418137/industrial-hemps-14b-projected-growth-an-investment-opportunity-too-good-to-miss">producing hemp-derived products</a>, affecting profitability and investment opportunities.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a></li>
</ul>
Image generated with AI tools.

Cannabis

Government

Regulations

FLGC

Synthetic Cannabinoids Could Be Federally Banned Under New Senate Bill To Regulate Hemp-Derived Products

TD Cowen analyst Oliver Chen maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Buy and lowers the price target from $26 to $25.

LEVI

TD Cowen Maintains Buy on Levi Strauss, Lowers Price Target to $25

In 2016, Warren Buffett, the legendary investor and CEO of Berkshire Hathaway, openly criticized Donald Trump during his presidential campaign. Buffett, a Democrat, was vocal about his support for Hillary Rodham Clinton and didn't hold back regarding Trump's controversial remarks and refusal to release his tax returns.&nbsp;
Don't Miss:
<ul>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>
<a href="https://www.benzinga.com/general/24/02/37264271/warren-buffett-exposed-the-reason-for-trumps-failed-business-ventures-decades-before-the-fraud-case">Buffett challenged Trump to release his tax returns</a> and even disclosed his own, countering Trump's claims that Buffett took a massive deduction. &#8220;I have copies of all 72 of my returns and none uses a carry forward,&#8221; <a href="https://www.benzinga.com/general/23/12/36217808/trump-once-accused-warren-buffett-of-tax-evasion-despite-his-own-refusal-to-release-tax-returns-buff">Buffett said at the time</a>.&nbsp;
Trump made this assertion in reaction to criticism about his 1995 $916 million loss, which, according to reports, may have allowed him to avoid paying federal income taxes for several years.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Many predicted that Buffett&#8217;s investments might suffer if Trump won. But what transpired was very different. The stock market soared following Trump&#8217;s victory and Buffett&#8217;s company, Berkshire Hathaway, had one of its finest months in six years.&nbsp;
Despite Buffett's public disapproval of Trump's politics, the market&#8217;s response to the new administration's promises of tax cuts and deregulation benefited many of his holdings, especially those in financial services.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Berkshire Hathaway started as a struggling textile business but has since become a massive company that owns or invests in businesses across various industries, such as insurance, energy and everyday products. It holds big investments in companies like JPMorgan Chase, Goldman Sachs and Coca-Cola, among many others.&nbsp;
When Trump got elected, many on Wall Street thought his plans for higher interest rates and fewer regulations would benefit financial companies, which in turn helped boost Berkshire's profits.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Buffett&#8217;s refusal to let politics affect his investing choices is evidence of his investing philosophy. <a href="https://www.benzinga.com/general/education/24/08/40225783/warren-buffetts-approach-to-investing-in-election-years">Even though he backed Clinton</a>, he clarified that Berkshire would prosper regardless of the election outcome.
As he told shareholders then, &#8220;Berkshire would continue to do fine no matter which candidate was elected president.&#8221; Buffett's confidence was well-placed and his company prospered under Trump's presidency.
As we approach the 2024 election, people are curious<a href="https://www.benzinga.com/news/24/09/40956172/trump-vs-harris-will-warren-buffett-display-a-blue-or-red-dot-in-his-front-yard-neighbors-wait-to-se"> whether Buffett will support Kamala Harris</a>. People in his Omaha neighborhood are checking to see if his front yard will display a &#8220;blue-dot&#8221; sign for Democratic support. A neighbor started this grassroots movement to show Democratic support in a mostly Republican neighborhood. Although Buffett hasn&#8217;t disclosed his position, his daughter already has two blue-dot signs in her yard.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/charlie-munger-100k">Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</a></li>
</ul>

Warren Buffett Spoke Out Against Trump In 2016. Ironically, He Was A Big Winner After Trump's Election Victory

RKLB

Rocket Lab shares are trading higher after Keybanc raised its price target on the stock from $8 to $11.

GameStop Shares Spike In Volume, Turn Positive

Nike (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) just announced that its current CEO has retired, and it&#39;s bringing in a long-time employee to take the helm. Elliott Hill will become Nike&#39;s CEO on Oct. 14. He hopes to be the new face the company needs to turn its fortunes around.
I&#39;ll detail Nike&#39;s history with lame-duck CEO John Donahoe and whether Hill is truly the spark needed to reignite the ailing consumer discretionary company.
<h2>How Donahoe Led Nike Astray</h2>
Since Donahoe took over as CEO of Nike in Jan. 2020, the company&#39;s performance has been disappointing, to say the least. Shares are down 14% over that time, greatly underperforming their sector. The Consumer Discretionary Select Sector SPDR Fund (ARCA: XLY) has managed to rise by 57%. Revenue has increased slowly over that period, rising a total of just 20% in just under four years.
The first few months of Donahoe&#39;s tenure may have tainted his overall strategy for the company. He entered the head role just two months before the beginning of COVID-19 lockdowns in the United States. In the following quarters, Nike&#39;s direct-to-consumer revenue stream saw massive growth. Donahoe believed this trend would continue and aimed to shift more of the company&#39;s revenue toward this business.
On the surface, it doesn&#39;t seem like a bad idea. Direct-to-consumer sales usually have higher margins, and companies cut out the middleman wholesalers, letting them keep more profit. However, it somewhat discounts the fact that going to the store and trying on a pair of shoes is a key element of the purchasing process for many.
But, more importantly, it also left brick-and-mortar stores with a dearth of inventory now that Nike was sending less supply. Notably, the percentage of Foot Locker&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) inventory spending on Nike dropped from 75% in 2020 to 55% by the end of 2022. This opened the door for competitors to gain customer exposure, as Foot Locker needed inventory from different sources.
Previously unknown brands like On (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) and Hoka were able to take advantage of this. In 2023, On received 63% of its revenue from wholesale sources and has seen its stock price rise over 50% in the past three years. Nike failed to realize how its overwhelming presence in retail stores kept new competitors from becoming well-known. The same was true for online wholesalers. Nike completely cut ties with e-commerce vendors like Zappos, causing them to need other inventory.
Another big criticism of the firm was Nike&#39;s push to sell through mobile apps. They wanted to innovate how they exposed customers to their products, but they weren&#39;t innovating the products themselves. They relied too much on very successful products and styles. They stopped pushing to create the next blockbuster shoe.
<h2>History Shows Hill Can Bring Nike Back to Its Roots and Stock Market Success</h2>
Elliott Hill began his career as an intern at Nike in 1988, just before the company had started cementing itself as the must-own shoe brand worldwide. Before its release, he watched the company&#39;s first &quot;Just Do It&quot; ad in a theater with other employees. Hill has a marketing background. He eventually worked his way up the company to oversee all commercial and marketing operations for Nike and its Jordan brand. He retired in 2020.
In the eyes of many, this is exactly what Nike needs right now. Nike has begun to move back toward relationships with wholesalers. Hill should help speed up this process. He likely worked directly with wholesale partners in his previous role. Also, after 30 years at the company, he saw all the successes and failures in product innovation and marketing that made Nike the top name in footwear.
The CEO before Donahoe was Matt Parker, a former sneaker designer. Under his reign, starting in 2006, Nike&#39;s stock provided a total return of 1,047% until Donahoe took over. That&#39;s over four times the total return of the S&amp;P 500 over that period. Donahoe, on the other hand, joined Nike after leading a cloud computing company.
<h2>Nike&#39;s Future: What to Watch For</h2>
Clearly, Nike performs better when its leader is steeped in product knowledge. Donahoe&#39;s hiring is a welcome return to that idea and has a great chance to change the market&#39;s tune on Nike. Still, it&#39;s important to hear the details of Elliot&#39;s plan before rushing back into the stock. Nike will likely provide more clarity around that at its Investor Day on Nov. 19.
The article &quot;<a href="https://www.marketbeat.com/originals/nikes-new-ceo-could-return-the-company-to-stock-market-glory/">Nike&#39;s New CEO Could Return the Company to Stock Market Glory</a>&quot; first appeared on MarketBeat.

Mid Cap

Events

ONON

Select Sector SPDR-Consumer Discretionary

Nike's New CEO Could Return the Company to Stock Market Glory

BlackBerry shares are trading lower. The company reported Q3 financial results.

In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16, with patients reporting significantly greater improvement in symptoms
Safety profile in PSORIATYK SCALP was consistent with the established safety profile of Sotyktu
In the real-world RePhlect registry of patients, six months of Sotyktu treatment was consistent with the efficacy outcomes observed in the POETYK clinical studies for psoriasis
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54127020&amp;newsitemid=20240925005092&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=bea69efca57c5230176a4c6a25a3865c">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu (deucravacitinib) for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in the scalp-specific Physician's Global Assessment (ss-PGA) response of 0 or 1 (clear/almost clear) at 16 weeks, with more than three times as many patients achieving ss-PGA 0/1 with Sotyktu treatment compared to those on placebo (48.5% versus 13.7%, respectively; p&lt;0.0001).
The new PSORIATYK SCALP efficacy and safety results (oral presentation FC04.07, abstract #5627), patient-reported outcomes (oral presentation FC06.06, abstract #5390) and 23 additional abstracts are being presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands taking place September 25-28, 2024.

Bristol Myers Squibb Presents New Data From 2-Trials Demonstrating Sotyktu Efficacy In both Moderate-To-Severe Scalp Psoriasis And In A Real-World Setting; In The Phase 3b/4 PSORIATYK SCALP Sotyktu Was Superior To Placebo Across All Primary And Secondary Endpoints At Week 16, With Patients Reporting Significantly Greater Improvement In Symptoms

BTIG analyst Jake Fuller maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Buy and raises the price target from $150 to $175.

EXPE

BTIG Maintains Buy on Expedia Group, Raises Price Target to $175

BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers

enVVeno Medical Corp (NVNO) is near the top in its industry group according to InvestorsObserver. NVNO gets an overall rating of 83. That means it scores higher than 83 percent of stocks. enVVeno Medical Corp gets a 100 rank in the Medical Devices industry. Medical Devices is number 63 out of 148 industries. NVNO has an Ov

Should Medical Devices Stock enVVeno Medical Corp (NVNO) Be in Your Portfolio Wednesday?

enVVeno: The Road To Approval Seems Open From Here On

The 77 rating InvestorsObserver gives to enVVeno Medical Corp (NVNO)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 98 percent of stocks in the Healthcare sector, NVNOâ€&#x2122;s 77 overall rating means the stock scores better than 77 of all stocks. NVNO has an Overall Score of 77. Find out

Is enVVeno Medical Corp (NVNO) Stock a Bad Value Tuesday?

The latest update is out from enVVeno Medical (NVNO). enVVeno Medical Corporation revealed promising topline results from the SAVVE U.S. pivotal tr...

enVVeno Medical's VenoValve Trial Shows Promising Results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
enVVeno Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvno-stock-quote/">NVNO</a>) just reported results for the first quarter of 2024.<ul><li>enVVeno Medical reported earnings per share of -31 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nvno-stock-earnings-envveno-medical-for-q1-of-2024/">NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024

enVVeno Medical reports Q1 results

enVVeno Medical reports Q2 results

enVVeno Medical offers to sell common stock

enVVeno Medical stock falls after it prices $15M securities offering

BIAF

BYSI

LIFW

NVNO

TCBP

XRTX

ZCMD

Press Releases

JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024

Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Earnings

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Management

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

ANVS

AREC

CNSP

MBRX

OTLK

PALI

RMCO

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

HeartBeam

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

Hyperfine

Iridex

Know Labs

LENSAR

Lucid Diagnostics

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Modular Medical

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Tech

Owlet

Pro-Dex

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Sensus Healthcare

Vivani Medical

EnVVeno Medical shares are trading lower after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.

Comments

enVVeno Medical

Intérêt court

enVVeno Medical (NASDAQ:NVNO) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL